Anders Wahlin

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/670737/publications.pdf

Version: 2024-02-01

125 papers 4,728 citations

33 h-index 65 g-index

125 all docs

 $\begin{array}{c} 125 \\ \text{docs citations} \end{array}$

125 times ranked

5118 citing authors

#	Article	IF	CITATIONS
1	Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. Blood, 2009, 113, 4179-4187.	1.4	811
2	Continuing high early death rate in acute promyelocytic leukemia: a population-based report from the Swedish Adult Acute Leukemia Registry. Leukemia, 2011, 25, 1128-1134.	7.2	276
3	Arterial and venous thrombosis in monoclonal gammopathy of undetermined significance and multiple myeloma: a population-based study. Blood, 2010, 115, 4991-4998.	1.4	204
4	Characterization and prognostic features of secondary acute myeloid leukemia in a populationâ€based setting: <scp>A</scp> report from the <scp>S</scp> wedish <scp>A</scp> cute <scp>L</scp> eukemia <scp>R</scp> egistry. American Journal of Hematology, 2015, 90, 208-214.	4.1	202
5	Adverse drug reactions as a cause for admissions to a department of internal medicine. Pharmacoepidemiology and Drug Safety, 2002, 11, 65-72.	1.9	168
6	Management of polycythaemia vera, essential thrombocythaemia and myelofibrosis with hydroxyurea*. European Journal of Haematology, 2009, 41, 375-381.	2.2	146
7	Geriatricâ€Based Versus General Wards for Older Acute Medical Patients: A Randomized Comparison of Outcomes and Use of Resources. Journal of the American Geriatrics Society, 2000, 48, 1381-1388.	2.6	140
8	Risk of plasma cell and lymphoproliferative disorders among 14621 first-degree relatives of 4458 patients with monoclonal gammopathy of undetermined significance in Sweden. Blood, 2009, 114, 791-795.	1.4	133
9	Congenital dyserythropoietic anemias: molecular insights and diagnostic approach. Blood, 2013, 122, 2162-2166.	1.4	127
10	Monoclonal gammopathy of undetermined significance and risk of infections: a population-based study. Haematologica, 2012, 97, 854-858.	3.5	110
11	Patterns of survival and causes of death following a diagnosis of monoclonal gammopathy of undetermined significance: a population-based study. Haematologica, 2009, 94, 1714-1720.	3.5	95
12	Attitude towards remission induction for elderly patients with acute myeloid leukemia influences survival. Leukemia, 2006, 20, 42-47.	7.2	91
13	Reversal of myelofibrosis by hydroxyurea. European Journal of Haematology, 1990, 44, 33-38.	2.2	89
14	Monoclonal gammopathy of undetermined significance and risk of skeletal fractures: a population-based study. Blood, 2010, 116, 2651-2655.	1.4	89
15	Congenital dyserythropoietic anemia type III (CDA III) is caused by a mutation in kinesin family member, KIF23. Blood, 2013, 121, 4791-4799.	1.4	88
16	Chlorambucil/prednisone vs. CHOP in symptomatic low-grade non-Hodgkin's lymphomas: A randomized trial from the Lymphoma Group of Central Sweden. Annals of Oncology, 1994, 5, S67-S71.	1.2	84
17	Interaction between haemochromatosis and transferrin receptor genes in different neoplastic disorders. Carcinogenesis, 1999, 20, 1231-1233.	2.8	79
18	Prognostic significance of risk group stratification in elderly patients with acute myeloid leukaemia. British Journal of Haematology, 2001, 115, 25-33.	2.5	79

#	Article	IF	CITATIONS
19	Renal Concentrating Capacity in Longâ€Term Lithium Treatment and after Withdrawal of Lithium. Acta Medica Scandinavica, 1980, 207, 309-314.	0.0	78
20	Personal and family history of immune-related conditions increase the risk of plasma cell disorders: a population-based study. Blood, 2011, 118, 6284-6291.	1.4	74
21	Haematopoetic stem cell transplantation for refractory autoimmune cytopenia. British Journal of Haematology, 2004, 125, 749-755.	2.5	73
22	Cytogenetic abnormalities and leukemic transformation in hydroxyurea-treated patients with Philadelphia chromosome negative chronic myeloproliferative disease. Cancer Genetics and Cytogenetics, 1990, 49, 57-67.	1.0	64
23	Patterns of hematologic malignancies and solid tumors among 37,838 firstâ€degree relatives of 13,896 patients with multiple myeloma in Sweden. International Journal of Cancer, 2009, 125, 2147-2150.	5.1	63
24	Localization of the gene for congenital dyserythropoietic anemia type III, CDAN3, to chromosome 15q21-q25. Human Molecular Genetics, 1995, 4, 109-112.	2.9	62
25	Hematopoietic stem cell transplantation rates and longâ€ŧerm survival in acute myeloid and lymphoblastic leukemia. Cancer, 2011, 117, 4238-4246.	4.1	51
26	Highâ€dose cytarabine in upfront therapy for adult patients with acute lymphoblastic leukaemia. British Journal of Haematology, 2002, 118, 748-754.	2.5	50
27	Lithium Therapy and Thyroid Function Tests. Neuropsychobiology, 1984, 11, 39-43.	1.9	48
28	Incidence and prognostic significance of karyotypic subgroups in older patients with acute myeloid leukemia: the Swedish population-based experience. Blood Cancer Journal, 2014, 4, e188-e188.	6.2	48
29	Measurement of iron and zinc isotopes in human whole blood: Preliminary application to the study of HFE genotypes. Journal of Trace Elements in Medicine and Biology, 2005, 19, 55-60.	3.0	45
30	Intravascular haemolysis and increased prevalence of myeloma and monoclonal gammopathy in congenital dyserythropoietic anaemia, type III. European Journal of Haematology, 1994, 52, 42-46.	2.2	42
31	IMPAIRMENT OF RENAL CONCENTRATING CAPACITY BY LITHIUM. Lancet, The, 1978, 311, 778-779.	13.7	38
32	Results of riskâ€adapted therapy in acute myeloid leukaemia. A longâ€term populationâ€based followâ€up study. European Journal of Haematology, 2009, 83, 99-107.	2.2	35
33	Angioid streaks are part of a familial syndrome of dyserythropoietic anaemia (CDA III). British Journal of Haematology, 1997, 98, 845-849.	2.5	34
34	Remission rate and survival in acute myeloid leukemia: Impact of selection and chemotherapy. European Journal of Haematology, 1991, 46, 240-247.	2.2	34
35	Intestinal permeability in patients with acute myeloid leukemia. European Journal of Haematology, 1998, 61, 250-254.	2.2	33
36	No benefit from adding GM-CSF to induction chemotherapy in transforming myelodysplastic syndromes: better outcome in patients with less proliferative disease. Leukemia, 2003, 17, 1827-1833.	7.2	32

#	Article	IF	Citations
37	Evaluation of Serial Bone Xâ€ray Examination in Multiple Myeloma. Acta Medica Scandinavica, 1982, 212, 385-387.	0.0	28
38	Improved Survival in Multiple Myeloma with Renal Failure. Acta Medica Scandinavica, 1987, 221, 205-209.	0.0	28
39	Individual Quality Assessment of Autografting by Probability Estimation for Clinical Endpoints: A Prospective Validation Study from the European Group for Blood and Marrow Transplantation. Biology of Blood and Marrow Transplantation, 2013, 19, 1670-1676.	2.0	26
40	Interaction between haemochromatosis and transferrin receptor genes in multiple myeloma. Lancet, The, 1998, 352, 1285-1286.	13.7	25
41	Induction chemotherapy and post-remission imatinib therapy for de NovoBCR-ABL-positive AML. American Journal of Hematology, 2006, 81, 470-471.	4.1	25
42	Ferritinemia and serum inflammatory cytokines in Swedish adults with Gaucher disease type 1. Blood Cells, Molecules, and Diseases, 2018, 68, 35-42.	1.4	25
43	Secondary Acute Myeloid Leukemia and the Role of Allogeneic Stem Cell Transplantation in a Population-Based Setting. Biology of Blood and Marrow Transplantation, 2019, 25, 1770-1778.	2.0	25
44	Kidney Function in Patients with Affective Disorders with and without Lithium Therapy. International Pharmacopsychiatry, 1980, 15, 253-259.	0.4	24
45	Intensive treatment in order to minimize the ph‐positive clone in chronic myelogenic leukemia. Stem Cells, 1993, 11, 73-76.	3.2	21
46	ECG Changes during Lithium Therapy. Acta Medica Scandinavica, 1984, 216, 101-104.	0.0	21
47	Reduction in WT1 Gene Expression During Early Treatment Predicts the Outcome in Patients With Acute Myeloid Leukemia. Diagnostic Molecular Pathology, 2012, 21, 225-233.	2.1	21
48	Mitoxantrone and cytarabine versus daunorubicin and cytarabine in previously untreated patients with acute myeloid leukemia. Cancer Chemotherapy and Pharmacology, 1991, 28, 480-483.	2.3	20
49	Autologous and allogeneic stem cell transplantation in adult ALL: the Swedish Adult ALL Group experience. Bone Marrow Transplantation, 2005, 35, 1141-1148.	2.4	20
50	Intensive Treatment and Stem Cell Transplantation in Chronic Myelogenous Leukemia: Long-Term Follow-Up. Acta Haematologica, 2005, 113, 155-162.	1.4	20
51	Renal Function in Familial Amyloidosis with Polyneuropathy. Acta Medica Scandinavica, 1982, 212, 233-236.	0.0	20
52	Progression of bone marrow fibrosis in patients with essential thrombocythemia and polycythemia vera during anagrelide treatment. Medical Oncology, 2007, 24, 63-70.	2.5	19
53	Allogeneic haematopoietic stem-cell transplantation with reduced intensity conditioning for advanced stage Hodgkin's lymphoma in Sweden: high incidence of post transplant lymphoproliferative disorder. Bone Marrow Transplantation, 2011, 46, 870-875.	2.4	18
54	Intensive Treatment in order to Minimize the Ph-Positive Clone in Chronic Myelogenic Leukemia. Leukemia and Lymphoma, 1992, 7, 55-57.	1.3	16

#	Article	IF	Citations
55	Improved outcome in adult acute myeloid leukemia is almost entirely restricted to young patients and associated with stem cell transplantation. European Journal of Haematology, 2002, 68, 54-63.	2.2	16
56	Long-Term Lithium Treatment and Renal Functions. Neuropsychobiology, 1984, 11, 33-38.	1.9	15
57	Emergence of Philadelphia positive chronic myeloid leukaemia during treatment with hydroxyurea for Philadelphia negative essential thrombocythaemia. European Journal of Haematology, 2003, 70, 240-241.	2.2	15
58	Bone Marrow Hyaluronan Distribution in Patients with Acute Myeloid Leukemia. Medical Oncology, 2005, 22, 071-078.	2.5	15
59	Urine Microscopy as Screening Method for Bacteriuria. Acta Medica Scandinavica, 1982, 211, 209-211.	0.0	14
60	Staging of Idiopathic Myelofibrosis: <i>Significance of Haemoglobin Value and Reticulocyte Count</i> Acta Medica Scandinavica, 1985, 218, 487-491.	0.0	14
61	Failure matters: unsuccessful cytogenetics and unperformed cytogenetics are associated with a poor prognosis in a populationâ€based series of acute myeloid leukaemia. European Journal of Haematology, 2015, 94, 419-423.	2.2	14
62	Glycoconjugate abnormalities in patients with congenital dyserythropoietic anaemia type I, II and III. British Journal of Haematology, 2001, 114, 907-913.	2.5	13
63	Melphalanâ€Related Leukemia in Multiple Myeloma. Acta Medica Scandinavica, 1982, 211, 203-208.	0.0	13
64	Hyperferritinemia is associated with low incidence of graft versus host disease, high relapse rate, and impaired survival in patients with blood disorders receiving allogeneic hematopoietic stem cell grafts. Medical Oncology, 2011, 28, 552-558.	2.5	13
65	Allogeneic hematopoietic stem cell transplant with reduced-intensity conditioning for chronic lymphocytic leukemia in Sweden: does donor T-cell engraftment 3 months after transplant predict survival?. Leukemia and Lymphoma, 2012, 53, 1699-1705.	1.3	13
66	Serum thymidine kinase in congenital dyserythropoietic anaemia type III. British Journal of Haematology, 1994, 87, 653-654.	2.5	12
67	Relation between harvest success and outcome after autologous peripheral blood stem cell transplantation in multiple myeloma. European Journal of Haematology, 2004, 73, 263-268.	2.2	12
68	Fecal calprotectin as a biomarker of intestinal graft versus host disease after allogeneic hematopoietic stem cell transplantation. Scientific Reports, 2015, 5, 7920.	3.3	12
69	Hydroxyurea Treatment of Myeloproliferative Disorders. Acta Medica Scandinavica, 1987, 222, 169-174.	0.0	11
70	Staging and survival in multiple myeloma. Scandinavian Journal of Haematology, 2009, 33, 22-26.	0.0	11
71	Genital Graft-versus-host Disease in a Male Following Allogeneic Stem Cell Transplantation. Acta Dermato-Venereologica, 2007, 87, 367-368.	1.3	10
72	Hiccups and severe hyponatremia associated with high-dose cyclophosphamide in conditioning regimen for allogeneic stem cell transplantation. American Journal of Hematology, 2007, 82, 88-88.	4.1	10

#	Article	IF	CITATIONS
73	Co-existence of pseudo-Chediak–Higashi anomaly and double minutes containing C-MYC oncogene in three patients with AML M2. Leukemia, 2002, 16, 152-154.	7.2	9
74	Differential Count of Urinary Leucocytes and Renal Epithelial Cells by Phase Contrast Microscopy. Acta Medica Scandinavica, 1975, 198, 505-509.	0.0	9
75	Myeloablative allogeneic stem cell transplantation for lymphoblastic lymphoma in Sweden: A retrospective study. American Journal of Hematology, 2011, 86, 709-710.	4.1	9
76	Poor Outcome in Secondary Acute Myeloid Leukemia (AML): A First Report From the Population-Based Swedish Acute Leukemia Registry. Blood, 2012, 120, 130-130.	1.4	9
77	A Pilot Study of Piperacillin and Ciprofloxacin as Initial Therapy for Fever in Severely Neutropenic Leukemia Patients. Scandinavian Journal of Infectious Diseases, 1992, 24, 467-475.	1.5	8
78	Evidence for a bimodal relation between serum lysozyme and prognosis in 232 patients with acute myeloid leukaemia. European Journal of Haematology, 2003, 70, 26-33.	2.2	7
79	Comparison of busulphan, hydroxyurea and allogeneic bone marrow transplantation (BMT) in chronic myeloid leukaemia: BMT prolongs survival. The Hematology Journal, 2004, 5, 462-466.	1.4	7
80	Fludarabine, Cyclophosphamide and Rituximab (FCR) induced pulmonary hypertension in Waldenström macroglobulinemia. Leukemia and Lymphoma, 2008, 49, 1209-1211.	1.3	7
81	Outcome of a multicenter treatment program including autologous or allogeneic bone marrow transplantation for <i>de novo</i> acute myeloid leukemia. European Journal of Haematology, 1997, 58, 233-240.	2.2	7
82	Decreasing early mortality in acute myeloid leukaemia in Sweden 1997–2014: improving performance status is a major contributing factor. British Journal of Haematology, 2020, 188, 187-191.	2.5	7
83	Nonfamilial Polycystic Kidneys without Enlargement. Nephron, 1985, 39, 134-140.	1.8	6
84	Indications for and Referrals to Oral Care for Cancer Patients in a County Hospital. Acta Oncol \tilde{A}^3 gica, 1996, 35, 743-748.	1.8	6
85	The Urinary Sediment in Endemic Benign Nephropathy. Acta Medica Scandinavica, 1977, 202, 51-54.	0.0	6
86	Long-term survival following allogeneic or syngeneic stem cell transplant for follicular lymphoma in Sweden. Leukemia and Lymphoma, 2011, 52, 69-71.	1.3	6
87	Amsacrine, cytarabine and etoposide in the treatment of bad prognosis acute myeloid leukemia. Medical Oncology and Tumor Pharmacotherapy, 1989, 6, 199-205.	1.1	6
88	Successful mobilization of Ph-negative blood stem cells with intensive chemotherapy + G-CSF in patients with chronic myelogenous leukemia in first chronic phase. Leukemia and Lymphoma, 2006, 47, 1768-1773.	1.3	5
89	Failure of Chlorothiazide to Improve Urinary Concentrating Capacity in Lithiumâ€Treated Patients. Acta Medica Scandinavica, 1980, 207, 195-196.	0.0	5
90	Response to Busulphan Treatment of Paroxysmal Nocturnal Hemoglobinuria and Myelofibrosis in One and the Same Patient. Acta Medica Scandinavica, 1981, 209, 133-135.	0.0	5

#	Article	IF	Citations
91	Retrospective Survey on the Prevalence and Outcome of Prior Autoimmune Diseases in Patients with Aplastic Anemia Reported to the Registry of the European Group for Blood and Marrow Transplantation. Acta Haematologica, 2010, 124, 19-22.	1.4	5
92	Differential Count of Urinary Leukocytes and Renal Epithelial Cells. Upsala Journal of Medical Sciences, 1977, 82, 43-47.	0.9	4
93	Plasma Proteins and Anti-Kidney Antibodies in Renal Carcinoma. Scandinavian Journal of Urology and Nephrology, 1982, 16, 163-166.	1.4	4
94	T-cell subsets in multiple myeloma. Blut, 1985, 51, 291-295.	1.2	4
95	Comparison of Efficacies of Ondansetron and Dixyrazine for Prophylaxis of Emesis During Induction Treatment in Acute Myelogenous Leukemia: A Pilot Study. Acta Oncológica, 1997, 36, 229-230.	1.8	4
96	Chronic lymphocytic leukemia with osteolytic Richter's syndrome mimicking myeloma bone disease shows no over-expression of DKK1. Leukemia and Lymphoma, 2006, 47, 1987-1988.	1.3	4
97	The Urinary Sediment in Hydronephrosis. Acta Medica Scandinavica, 1977, 201, 449-452.	0.0	4
98	Differential Count and Quantitative Estimation of Granulocytes, Mononuclear Leukocytes and Renal Epithelial Cells in Urine. Upsala Journal of Medical Sciences, 1978, 83, 109-114.	0.9	3
99	Philadelphia chromosome negative acute lymphoblastic leukemia preceding Philadelphia positive chronic myelogenous leukemia. Cancer Genetics and Cytogenetics, 1989, 39, 147-152.	1.0	3
100	Identification of Renal Tubular Epithelial Cells in Urine with Immunofluorescence. Acta Medica Scandinavica, 1979, 205, 587-591.	0.0	3
101	Treatment of Advanced Bone Marrow Neoplasms with Ifosfamide Combinations. Scandinavian Journal of Haematology, 1984, 32, 95-100.	0.0	3
102	Salvage High-Dose Chemotherapy for Relapsed Pure Seminoma in the Last 10 Years: Results From the European Society for Blood and Marrow Transplantation Series 2002-2012. Clinical Genitourinary Cancer, 2017, 15, 163-167.	1.9	3
103	Myelomaâ€Associated Cardiac Amyloidosis: A Case Report. Acta Medica Scandinavica, 1984, 215, 189-192.	0.0	2
104	High incidence of chronic graft-versus-host disease after myeloablative allogeneic stem cell transplantation for chronic lymphocytic leukemia in Sweden: graft-versus-leukemia effect protects against relapse. Medical Oncology, 2013, 30, 762.	2.5	2
105	URINE MICROSCOPY. Lancet, The, 1978, 312, 1052.	13.7	1
106	Multiple DNA Rearrangements in the BCL2 Region in a Patient With Follicular Lymphoma. Genes Chromosomes and Cancer, 1991, 3, 390-393.	2.8	1
107	Myelodysplastic Syndromesâ \in "A Population-Based Study on Transformation and Survival. Acta Oncol \tilde{A}^3 gica, 1995, 34, 473-478.	1.8	1
108	Chromosome aberrations including $der(6)t(2;6)(p15;p21.3)$ and $der(22)t(3;22)(p21;p11)$ in the evolution of essential thrombocythemia to myelofibrosis with myeloid metaplasia. Cancer Genetics and Cytogenetics, 2006, 165, 87-89.	1.0	1

#	Article	IF	Citations
109	Accumulating evidence for a role of p53 in multiple drug resistant Acute Myeloid Leukemia. Leukemia and Lymphoma, 2008, 49, 383-384.	1.3	1
110	Effects of Plasmapheresis on the Plasma Concentration of Proteins Used to Monitor the Disease Process in Multiple Myeloma. Acta Medica Scandinavica, 1988, 223, 263-267.	0.0	1
111	Chronic monocytic leukemia terminating in blastic transformation. Blut, 1986, 53, 405-409.	1.2	0
112	Factors Influencing the Efficacy of Platelet Transfusions in Acute Leukemia. Leukemia and Lymphoma, 1990, 2, 341-346.	1.3	0
113	Transplantation after reduced intensity conditioning in patients with acute myeloid leukaemia in Sweden. Biology of Blood and Marrow Transplantation, 2005, 11, 33.	2.0	0
114	Life table analysis for estimation of duration of aplasia after highâ€dose chemotherapy. European Journal of Haematology, 1990, 45, 284-285.	2.2	0
115	THE SIGNIFICANCE OF HANDMIRROR CELLS IN ACUTE MYELOCYTIC LEUKAEMIA TYPE M1 AND M2 AFTER WEAK CYTOSTATIC TREATMENT. Acta Pathologica, Microbiologica, Et Immunologica Scandinavica Section A, Pathology, 1986, 94A, 149-152.	0.3	0
116	Long-term survival after allogeneic stem cell transplant for relapsed large B cell lymphomas: a retrospective study. Leukemia and Lymphoma, 2012, 53, 503-505.	1.3	0
117	Increased Risk of Monoclonal Gammopathy of Undetermined Significance (MGUS) and Lymphoproliferative Tumors among 14689 First-Degree Relatives of 4488 MGUS Patients in Sweden Blood, 2007, 110, 660-660.	1.4	0
118	Copy Number Variations In Acute Leukemia with Cytogenetically Detected 11q23 Rearrangements. Blood, 2010, 116, 4835-4835.	1.4	0
119	Monoclonal Gammopathy of Undetermined Significance and Risk of Infections: A Population-Based Study. Blood, 2010, 116, 4053-4053.	1.4	O
120	Allogeneic Transplantation in First Remission Improves Outcome in Secondary Acute Myeloid Leukemia. Blood, 2014, 124, 281-281.	1.4	0
121	Improved Survival of Patients with Acute Myeloid Leukemia Following Implementation of Swedish National Guidelines: Results from the AML Registry 1997-2013. Blood, 2014, 124, 2269-2269.	1.4	0
122	Impact of response to induction chemotherapy (CT) and prior paclitaxel (TXL)-based CT on the outcome of salvage high-dose chemotherapy (HDCT) for relapsed germ-cell tumors (GCT) in the modern era: An EBMT Solid Tumors Working Party study Journal of Clinical Oncology, 2015, 33, 4535-4535.	1.6	0
123	Conventional-dose (CDCT) versus high-dose chemotherapy (HDCT) in the salvage management of relapsed pure seminoma: Results from an international database Journal of Clinical Oncology, 2015, 33, e15559-e15559.	1.6	0
124	Prevalence and Characteristics of Survivors from Adult Acute Myeloid Leukemia (AML) in Sweden 2014. Blood, 2015, 126, 4888-4888.	1.4	0
125	The Impact of Prior Malignancies on Second Malignancies and Survival in MM Patients: A Population-Based Study. Blood, 2016, 128, 3246-3246.	1.4	O